New antibiotics for skin and skin-structure infections

The Lancet Infectious Diseases

Volumn 14, Issue 8, 2014, Pages 659-661

  Tacconelli, Evelina ^a   Kern, Winfried V ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CEFTAROLINE; CLINDAMYCIN; DAPTOMYCIN; DELAFLOXACIN; LINEZOLID; OXACILLIN; TEDIZOLID; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NOTE; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL;

EID: 84904733664     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70798-4     Document Type: Note

References (13)

1. Global report on surveillance WHO, (accessed May 23, 2014). http://www.who.int.
2. Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008, 61:26-38.
3. Tacconelli E, De Angelis G, Cataldo MA, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009, 53:4264-4269.
4. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011, 11:30-38.
5. Zervos MJ, Freeman K, Vo L, Haque N, Pokharna H, Raut M, Kim M Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012, 50:238-245.
6. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2014, published online June 6. http://dx.doi.org/10.1016/S1473-3099(14)70737-6.
7. Prokocimer P, De Anda C, Fang E, Mehra P, Das A Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013, 309:559-569.
8. Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
9. Dryden MS Complicated skin and soft tissue infection. J Antimicrob Chemother 2010, 65(suppl 3):iii35-iii44.
10. McClaine RJ, Husted TL, Hebbeler-Clark RS, Solomkin JS Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis 2010, 50:1120-1126.
11. Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013, 7. CD008056.
12. Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res 2013, 5:447-457.
13. Jenks PJ, Laurent M, McQuarry S, Watkins R Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect 2014, 86:24-33.